First Thing, Daily Maverick's flagship newsletter

Join the 230 000 South Africans who read First Thing newsletter.

We'd like our readers to start paying for Daily Maverick

More specifically, we'd like those who can afford to pay to start paying. What it comes down to is whether or not you value Daily Maverick. Think of us in terms of your daily cappuccino from your favourite coffee shop. It costs around R35. That’s R1,050 per month on frothy milk. Don’t get us wrong, we’re almost exclusively fuelled by coffee. BUT maybe R200 of that R1,050 could go to the journalism that’s fighting for the country?

We don’t dictate how much we’d like our readers to contribute. After all, how much you value our work is subjective (and frankly, every amount helps). At R200, you get it back in Uber Eats and ride vouchers every month, but that’s just a suggestion. A little less than a week’s worth of cappuccinos.

We can't survive on hope and our own determination. Our country is going to be considerably worse off if we don’t have a strong, sustainable news media. If you’re rejigging your budgets, and it comes to choosing between frothy milk and Daily Maverick, we hope you might reconsider that cappuccino.

We need your help. And we’re not ashamed to ask for it.

Our mission is to Defend Truth. Join Maverick Insider.

Support Daily Maverick→
Payment options

Merck seeks first U.S. FDA authorization for Covid-19 t...

Newsdeck

Newsdeck

Merck seeks first U.S. FDA authorization for Covid-19 tablet

Signage outside Merck &; Co. headquarters in Kenilworth, New Jersey, U.S. Photographer: Christopher Occhicone/Bloomberg
By Reuters
11 Oct 2021 0

Oct 11 (Reuters) - Merck & Co Inc said on Monday it has applied for U.S. emergency use authorization for its tablet to treat mild-to-moderate patients of Covid-19, putting it on course to become the first oral antiviral medication for the disease. Its authorization could help change clinical management of Covid-19 as the pill can be taken at home. The treatment, molnupiravir, could halve the chances of death or being hospitalized for those most at risk of contracting severe Covid-19, according to the drugmaker.

Viral sequencing done so far have showed it is effective against all coronavirus variants, including Delta, Merck said.

The interim efficacy data on the drug, which has been developed with Ridgeback Biotherapeutics, had heavily impacted the shares of COVID-19 vacine makers when it was released last week.

Existing drugs include Gilead Sciences Inc’s infused antiviral remdesivir and generic steroid dexamethasone, both of which are generally only given once a patient has already been hospitalized.

Meanwhile, monoclonal antibody drugs from Regeneron Pharmaceuticals Inc and Eli Lilly have so far seen only limited uptake due to the difficulty in administering them.

(Reporting by Manas Mishra and Leroy Leo in Bengaluru; Editing by Arun Koyyur)

Information pertaining to Covid-19, vaccines, how to control the spread of the virus and potential treatments is ever-changing. Under the South African Disaster Management Act Regulation 11(5)(c) it is prohibited to publish information through any medium with the intention to deceive people on government measures to address COVID-19. We are therefore disabling the comment section on this article in order to protect both the commenting member and ourselves from potential liability. Should you have additional information that you think we should know, please email 

Gallery

Please peer review 3 community comments before your comment can be posted